May 22, 2022

Medical Trend

Medical News and Medical Resources

Israel released real-world research data of COVID-19 booster shot

Israel released real-world research data of COVID-19 booster shot



 

Israel released real-world research data of COVID-19 booster shot.

On October 29, 2021, the Clalit Research Institute of Israel and the Ministry of Health published a blockbuster study on Lancet, reporting the real-world protection of more than 720,000 people inoculated with the third dose of BNT162b2.

 

The study evaluated the protective power of 7 days after the third dose of 728,321 and compared it with people who received only two doses of 728,321, all of whom received the second dose for more than 5 months.

 

Israel released real-world research data of COVID-19 booster shot

 

 

Prevent an infection

The study showed that compared with subjects who received only 2 doses of vaccine, the third dose group had 88% protection against asymptomatic infections and 91% protection against symptomatic infections.

 

Israel released real-world research data of COVID-19 booster shot

 

Prevention of severe illness and death

Compared with subjects who completed only 2 doses of vaccination, BNT162b2 booster vaccination had a 93% protection against hospitalization, 92% protection against critical illness, and 81% protection against death.

 

Israel released real-world research data of COVID-19 booster shot

Real-world research in Israel shows that compared with standard vaccination, booster shots can significantly reduce the risk of infection, serious illness, and death.

 

The situation has changed in the United Kingdom, which has been slow to use booster needles, the United States, which partially uses booster needles, and Israel, which has fully used booster needles. As shown in 👇:

 

Israel released real-world research data of COVID-19 booster shot(Changes in new cases in the United Kingdom, the United States, and Israel)

 

As a global testing center for COVID-19, Israel took the unknown risk to overcome the obstacles of the global anti-epidemic countermeasures. The result is that the case fatality rate (0.61%) is much lower than that of the United Kingdom (1.56%) and the United States (1.62%).

 

This real-world protection data, together with Pfizer’s phase 3 clinical trial protection data, can be used as complete data on the effectiveness of the third dose of vaccination.

 

 

 

Reference:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02249-2/fulltext

(source:internet, reference only)


Disclaimer of medicaltrend.org